Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

Researchers at the National Center for Advancing Translational Sciences, part of the National Institutes of Health, have developed a system to accelerate the discovery of chemical compounds that inhibit an enzyme implicated in a number of cancers.

6 Sep 2018

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.

31 Aug 2018

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

Stephen Elledge, PhD, and his team did not set out to find therapies that could render tumors less resistant to therapy or make existing drugs more potent against a rare form of cancer. But these are precisely the clinical insights that their most recent study has yielded.

29 Aug 2018

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

To further advance the study and treatment of blood cancers, Perlmutter Cancer Center at NYU Langone Health has significantly expanded its Blood and Marrow Transplant Program.

20 Aug 2018

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly.

13 Aug 2018

New discovery could pave way for improved leukemia treatment

Previous research has revealed that patients with acute myeloid leukemia who also have a particular mutation in a gene called NPM1 have a higher rate of remission with chemotherapy. About one-third of leukemia patients possess this favorable mutation, but until now, how it helps improve outcomes has remained unknown.

9 Aug 2018

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

A comprehensive RNA and DNA sequencing platform benefits late-stage and drug-resistant multiple myeloma patients by determining which drugs would work best for them, according to results from a clinical trial published in JCO Precision Oncology in August.

9 Aug 2018

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

2 Aug 2018

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended broadening the existing marketing authorization for Darzalex® for use as frontline therapy.

28 Jul 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie, a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for venetoclax in combination with a hypomethylating agent or in combination with low-dose cytarabine for the treatment of newly diagnosed patients with acute myeloid leukemia who are ineligible for intensive chemotherapy.

20 Jul 2018

New study suggests testing urine and blood serum as better way to diagnose myeloma

When it comes to diagnosing a condition in which the plasma cells that normally make antibodies to protect us instead become cancerous, it may be better to look at the urine as well as the serum of our blood for answers, pathologists say.

13 Jul 2018

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 at the atomic level.

10 Jul 2018

Drug used in stem cell therapy may protect against smoke-induced lung injury

A drug used in stem cell therapy to treat certain cancers may also protect against cigarette smoke-induced lung injury.

5 Jul 2018

Streamlining and translating basic science discoveries into the clinic

To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.

2 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Hematopoietic stem cell transplant improves survival for multiple myeloma patients

Researchers at UC Davis have confirmed that autologous hematopoietic stem cell transplant improves survival for people suffering from multiple myeloma, yet many potentially eligible patients never undergo the procedure.

13 Jun 2018

Study finds increase in lifestyle-related cancers over the past decade

Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

4 Jun 2018

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

1 Jun 2018

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

New system accelerates discovery of chemical compounds that inhibit enzyme implicated in cancers

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Study yields therapeutic clues to combat drug resistance in rare aggressive cancer

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

NUS scientists develop new technology to customize optimal drug ‘cocktail’ for myeloma patients

New discovery could pave way for improved leukemia treatment

RNA and DNA sequencing platform matches broader swath of drugs to late-stage cancer patients

Scientists solve 60-year-old mystery of how thalidomide caused birth defects

Janssen’s Darzalex receives positive CHMP opinion for treating multiple myeloma patients

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

New study suggests testing urine and blood serum as better way to diagnose myeloma

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Drug used in stem cell therapy may protect against smoke-induced lung injury

Streamlining and translating basic science discoveries into the clinic

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Hematopoietic stem cell transplant improves survival for multiple myeloma patients

Study finds increase in lifestyle-related cancers over the past decade

MD Anderson and Amgen collaborate to accelerate early-stage oncology therapies

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in